• 제목/요약/키워드: Palliative treatment

검색결과 427건 처리시간 0.023초

골반부 전이성 종양의 수술적 치료 (Surgical Treatment of Metastatic Tumor in Pelvis)

  • 김재도;박웅;조명래;손정환;이영구
    • 대한골관절종양학회지
    • /
    • 제10권2호
    • /
    • pp.61-70
    • /
    • 2004
  • 목적: 골반부 전이성 종양의 수술적 치료 후 종양학적 결과, 기능 및 합병증의 발생을 통해 수술적 치료의 적응 가능성을 연구하고자 한다. 대상 및 방법: 1994년 5월부터 2003년 5월까지 골반부 전이성 종양 환자 중 고식적/수술적 치료를 받았던 9례/10례를 대상으로 하였으며 환자의 평균 연령은 57.6/48.0세, 남녀 비는 5:4/7:3이였다. 원발 병소로는 신장암과 자궁 경부암이 각 3례, 폐암, 골수종, 비호지킨 림프종이 각 2례, 유방암, 방광암, 고환암, 전립선암, 위암, 간암, 후복막 평활근육종이 각각 1례 이었다. 고식적 치료로는 방사선 단독 치료가 5례, 항암 화학 단독 치료가 1례, 방사선 치료와 항암 화학 요법의 병합 치료가 2례, 경피적 뼈시멘트 삽입술이 1례에서 행하여 졌으며, 수술적 치료로는 소파술 후 뼈시멘트 삽입술이 1례, 내골반 반절제술 후 Girdlestone 술식이 2례, 재건술이 7례에서 시행되었고, 재건술로는 뼈시멘트 삽입술이 1례, 방사선 조사 또는 저온 멸균 후 자가골 이식술 및 고관절 전치환술이 5례, saddle prosthesis를 이용한 관절 성형술이 1례에서 시행되었다. 치료 후 종양학적 결과 및 Eastern Cooperative Oncologic Group (ECOG) 운동 평가 지수, 술 후 합병증을 조사하였다. 결과: 고식적/수술적 치료군에서 종양학적 결과로는 NED 0/1례, AWD 2/6례, DOC 1/2례, DOD 6/1례였고, ECOG 운동 평가 지수는 고식적 치료군에서 치료 전 1.5에서 치료 후 4.3으로 악화되었으나 수술적 치료군에서는 2.6에서 2.2로 관찰되었다. 합병증으로는 금속 대치물 부전이 3례, 감염이 2례에서 관찰되었다. 결론: 골반부 전이성 종양의 수술 여부 및 수술의 방법은 환자의 상태, 원발 종양의 악성도 및 기대 생존 기간에 따라 결정되어야 될 것으로 사료되었다.

  • PDF

고식적 항암화학요법 후에 Capecitabine 단독치료에 반응을 보인 전이성 대장암 환자 1례 (Response to Capecitabine Treatment Following Palliative Chemotherapy for Metastatic Colorectal Cancer: A Case Report)

  • 박대화;김주석;강선형;문희석;성재규;정현용
    • Journal of Digestive Cancer Research
    • /
    • 제5권1호
    • /
    • pp.66-69
    • /
    • 2017
  • 대장암의 치료에 여러 약물이 사용되지만, 5-FU는 오랫동안 대장암의 항암치료의 근간이 되고 있다. Capecitabine은 경구 복용하는 5-FU의 전구체로서, 최근 전이성 대장암의 치료에 사용이 증가되고 있는 약물이다. 저자들은 전이성 대장암 환자에서 고식적인 항암화학요법으로 1차 치료로서 FOLFOX에 좋은 반응을 보였으나, 부작용으로 중단 후 2차 치료로서 Capecitabine 단독요법만을 시행하였음에도 지속적으로 좋은 반응을 보이며 추적관찰하고 있는 사례를 문헌고찰과 함께 보고하는 바이다.

  • PDF

전이를 동반한 진행성대장암의 항암 치료에 대한 접근 (Access of Anti-cancer Treatment for Advanced Colon Cancer with Metastasis)

  • 김현건
    • Journal of Digestive Cancer Research
    • /
    • 제1권1호
    • /
    • pp.6-16
    • /
    • 2013
  • 식생활의 서구화와 대장암 검진의 증가로 인하여 국내의 대장암 유병률은 지속적으로 증가하고 있으며, 최근 보고에 의하면 남자에서는 종양 발생률 2위, 여자에서는 종양 발생률의 3위를 차지하고 있다. 비록 대장내시경이 대장암의 진단과 선별검사에 아주 효과적인 방법이지만, 여전히 대장암의 20-25%는 이미 진단 당시에 전이를 동반하고 있는 것으로 되어 있다. 최근 10년 동안 이러한 전이성대장암의 고식적인 치료로 irinotecan과 oxaliplatin 등의 약제들의 개발과 이들의 다양한 조합에 관련된 연구들이 보고되어 왔으며, 분자생물학적인 발전에 힘입은 표적 치료제의 개발과 이에 대한 다양한 연구들은 향후에도 진행성대장암 환자들의 종양 반응률과 생존기간을 증가시킬 것으로 기대된다.

  • PDF

Carboplatin/5-fluorouracil as an Alternative to Cisplatin/5-Fluorouracil for Metastatic and Recurrent Head and Neck Squamous Cell Carcinoma and Nasopharyngeal Carcinoma

  • Kua, Voon Fong;Ismail, Fuad;Phua, Vincent Chee Ee;Aslan, Nik Muhd
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제14권2호
    • /
    • pp.1121-1126
    • /
    • 2013
  • Background: Palliative chemotherapy with cisplatin/5-fluorouracil (5FU) is the commonest regimen employed for metastatic and recurrent head and neck squamous cell carcinoma (SCCHN) and nasopharyngeal carcinoma (NPC). However, this regimen is cumbersome requiring 5 days of admission to hospital. Carboplatin/5FU may be an alternative regimen without compromising survival and response rates. This study aimed to compare the efficacy and toxicity of carboplatin/5FU regimen with the cisplatin/5FU regimen. Materials and Methods: This retrospective study looked at patients who had palliative chemotherapy with either cisplatin/5FU or carboplatin/5FU for metastatic and recurrent SCCHN and NPC. It included patients who were treated at UKMMC from $1^{st}$ January 2004 to $31^{st}$ December 2009 with either palliative IV cispaltin 75 $mg/m^2$ D1 only plus IV 5FU 750 $mg/m^2$ D1-5 infusion or IV Carboplatin AUC 5 D1 only plus IV 5FU 500 $mg/m^2$ D1-2 infusion plus IV 5FU 500 $mg/m^2$ D1-2 bolus. The specific objectives were to determine the efficacy of palliative chemotherapy in terms of overall response rate (ORR), median progression free survival (PFS) and median overall survival (OS) and to evaluate the toxicities of both regimens. Results: A total of 41 patients were eligible for this study. There were 17 in the cisplatin/5FU arm and 24 in the carboplatin/5FU arm. The ORR was 17.7 % for cisplatin/5FU arm and 37.5 % for carboplatin/5FU arm (p-value=0.304). The median PFS was 7 months for cisplatin/5FU and 9 months for carboplatin/5FU (p-value=1.015). The median OS was 10 months for cisplatin/5FU arm and 12 months for carboplatin/5FU arm (p-value=0.110). There were 6 treatment-related deaths (6/41=14.6%), four in the carboplatin/5FU arm (4/24=16.7%) and 2 in the cisplatin/5FU arm (2/17=11.8%). Grade 3 and 4 hematologic toxicity was also more common with carboplatin/5FU group, this difference being predominantly due to grade 3-4 granulocytopenia (41.6% vs. 0), grade 3-4 anemia (37.5% vs. 0) and grade 3-4 thrombocytopenia (16.6% vs. 0). Conclusions: Carboplatin/5FU is not inferior to cisplatin/5FU with regard to its efficacy. However, there was a high rate of treatment-related deaths with both regimens. A better alternative needs to be considered.

전이성 뇌종양의 방사선치료 성적 (Radiation Therapy for Brain Metastases)

  • 김일한;박찬일
    • Radiation Oncology Journal
    • /
    • 제2권1호
    • /
    • pp.33-39
    • /
    • 1984
  • One hundred and twenty patients with brain metastases were seen and evaluated in the Dept. of Therapeutic Radiology, Seoul National University Hospital between 1979 and 1983. Of these, 90 Patients received whole brain irradiation with 2,000 ra4 in 1 week or 3,000 rad in 2 weeks for Palliative Purpose and 30 patients failed to complete the planned treatment. Carcinoma of the lung(44 cases), choriocarcinoma(11 cases), breast(8 cases) were common Primary tumors of 90 patients receiving planned treatment. Symptomatic subjective response was obtained in $92\%$ of Patients and meurologic functional improvement was obtained in $42\%$ of patients. Median survival was 6.4 months in patients with complete treatment an·d less than 2 months in Patients with incomplete treatment, overall survival rate at 1 year and 2 year were $26\%,\;16\%$ in Patients with complete treatment and $8\%,\;0\%$ in patients with incomplete treatment. Primary site, extent of metastases and interval from diagnosis of primary tumor to brain metastases were identified as prognostic factors.

  • PDF

Psychometric Analysis of a Persian Version of the European Organization for Research and Treatment of Cancer OG25 Quality of Life Questionnaire in Oesophagogastric Cancer Patients

  • Hesari, Ali Esmaeili;Lari, Mohsen Asadi;Shandiz, Fatemeh Homai
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권6호
    • /
    • pp.2739-2745
    • /
    • 2014
  • Background: Health-related quality of life (HRQL) is a fundamental outcome in oncology patients and quality of life (QOL) assessment requires clinically relevant questionnaires. The purpose of this study was translation and definition of measurement properties and the clinical validity of Quality of Life Questionnaire (QLQ)-OG25 module in Persian patients with oesophagus, oesophagogastric junction (OGJ) or gastric cancers. Materials and Methods: The translation procedure followed European Organization for Research and Treatment of Cancer (EORTC) guidelines. Both EORTC QLQ-OG25 and a core questionnaire (EORTC QLQ-C30) were administered to patients with oesophagus (150), OG junction (93) and gastric (32) cancer undergoing multi-modal treatments. Convergent and discriminant validity, Cronbach's alpha coefficient and known-groups comparisons were used to examine reliability and validity. Results: In all, 275 patients (mean age 62 years) completed both questionnaires. Compliance rate was high and the questionnaire module was well accepted. We found good reliability for multi-item subscales of QLQ-OG25 (Cronbach's alpha coefficients 0.76-0.89). About 73% had TNM staging and scales distinguished between clinically distinct groups of patients. However, patients in palliative group experienced compromised functional status and worse treatment-associated symptoms than those in the potentially curative group. Test-retest scores were consistent. Multi-trait scaling analysis demonstrated good convergent and discriminant validity. Conclusions: Overall, the Persian version of QLQ-OG25 demonstrated psychometric and clinical validity that supports its application as a supplement to the original tool (EORTC QLQ-C30) when assessing HRQL in patients with upper-gastrointestinal (GI) cancer both in curative and palliative phases.

Surgical Management with Radiation Therapy for Metastatic Spinal Tumors Located on Cervicothoracic Junction : A Single Center Study

  • Park, Ho-Young;Lee, Sun-Ho;Park, Se-Jun;Kim, Eun-Sang;Lee, Chong-Suh;Eoh, Whan
    • Journal of Korean Neurosurgical Society
    • /
    • 제57권1호
    • /
    • pp.42-49
    • /
    • 2015
  • Objective : The cervicothoracic junction (CTJ) is a biomechanically and anatomically complex region that has traditionally posed problems for surgical access. In this retrospective study, we describe our clinical experiences of the treatment of metastatic spinal tumors at the CTJ and the results. Methods : From June 2006 to December 2011, 23 patients who underwent surgery for spinal tumors involving the CTJ were enrolled in our study. All of the patients were operated on through the posterior approach, and extent of resection was classified as radical, debulking, and simple neural decompression. Adjuvant radiation therapy (RT) was also considered. Visual analog scale score for pain assessment and Medical Research Council (MRC) grade for motor weakness were used, while pre- and post-operative performance status was evaluated using the Eastern Cooperative Oncology Group (ECOG). Results : Almost all of the patients were operated using palliative surgical methods (91.3%, 21/23). Ten complications following surgery occurred and revision was performed in four patients. Of the 23 patients of this study, 22 showed significant pain relief according to their visual analogue scale scores. Concerning the aspect of neurological and functional recovery, mean MRC grade and ECOG score was significantly improved after surgery (p<0.05). In terms of survival, radiation therapy had a significant role. Median overall survival was 124 days after surgery, and the adjuvant-RT group (median 214 days) had longer survival times than prior-RT (63 days) group. Conclusion : Although surgical procedure in CTJ may be difficult, we expect good clinical results by adopting a palliative posterior surgical method with appropriate preoperative preparation and postoperative treatment.

Radiation for persistent or recurrent epithelial ovarian cancer: a need for reassessment

  • Choi, Noorie;Chang, Ji Hyun;Kim, Suzy;Kim, Hak Jae
    • Radiation Oncology Journal
    • /
    • 제35권2호
    • /
    • pp.144-152
    • /
    • 2017
  • Purpose: The role of radiotherapy (RT) was largely deserted after the introduction of platinum-based chemotherapy, but still survival rates are disappointingly low. This study focuses on assessing the clinical efficacy of RT in relation to chemotherapy resistance. Materials and Methods: From October 2002 to January 2015, 44 patients were diagnosed with epithelial ovarian cancer (EOC) and treated with palliative RT for persistent or recurrent EOC. All patients received initial treatment with optimal debulking surgery and adjuvant platinum-based chemotherapy. The biologically effective dose (BED) was calculated with ${\alpha}/{\beta}$ set at 10. Ninety-four sites were treated with RT with a median BED of 50.7 Gy (range 28.0 to 79.2 Gy). The primary end-point was the in-field local control (LC) interval, defined as the time interval from the date RT was completed to the date any progressive or newly recurring disease within the RT field was detected on radiographic imaging. Results: The median follow-up duration was 52.3 months (range 7.7 to 179.0 months). The 1-year and 2-year in-field LC rates were 66.0% and 55.0%, respectively. Comparisons of percent change of in-field tumor response showed similar distribution of responses among chemoresistant and chemosensitive tumors. On multivariate analysis of predictive factors for in-field LC analyzed by sites treated, $BED{\geq}50Gy$ (hazard ratio, 0.4; confidence interval, 0.2-0.9; p = 0.025) showed better outcomes. Conclusion: Regardless of resistance to platinum-based chemotherapy, RT can be a feasible treatment modality for patients with persistent of recurrent EOC. The specific role of RT using updated approaches needs to be reassessed.

암환자의 마약성 진통제에 대한 신체적 의존을 경피적 Buprenorphine 패취를 통해 성공적으로 치료한 증례보고 (Successful Treatment with Transdermal Buprenorphine Patch in Opioid-Dependent Cancer Patients: Case Series)

  • 고세일;김정훈;이경원;강정훈
    • Journal of Hospice and Palliative Care
    • /
    • 제21권4호
    • /
    • pp.152-157
    • /
    • 2018
  • 암환자에서 암성 통증을 완화시키기 위한 강한 마약성 진통제의 사용이 늘어남에 따라, 마약성 진통제 관련 이상행동이 새로운 문제로 대두되고 있다. 비암성 환자에서의 마약성 진통제에 대한 중독 및 신체적 의존의 치료는 잘 알려져 있으나, 암환자, 특히 국내의 암환자에서는 이와 관련한 연구가 부족한 실정이다. 본 저자들은 강한 마약성 진통제에 대해 신체적 의존을 보여 부분 뮤-아편양 수용체 작용제인 buprenorphine으로 성공적으로 치료 받았던 열 명의 암환자들을 보고하고자 한다. 이는 암환자의 마약성 진통제에 대한 신체적 의존을 경피적 buprenorphine 패취로 치료할 수 있음을 보여준 첫 번째 보고이다.

Knowledge and Attitudes toward Advance Directives among Middle-Aged Women

  • Choi, Ji Won;Rhee, Yong Joo
    • Journal of Hospice and Palliative Care
    • /
    • 제24권2호
    • /
    • pp.74-84
    • /
    • 2021
  • Purpose: This study investigated knowledge of and attitudes toward advance directives (ADs) among middle-aged women in South Korea, their willingness to write ADs in the future, and the factors related to knowledge of and attitudes toward ADs. Methods: Data were collected using a self-administrated questionnaire completed by 154 middle-aged women aged 50 to 64 from February to March 2020. The questionnaire asked about participants' knowledge of and attitude toward ADs, willingness to write ADs in the future, experiences with life-sustaining treatment within their families, experience making decisions about life-sustaining treatment, and demographic characteristics. Results: Scores for both knowledge of and attitude toward ADs were relatively high. About 60% of participants gave wrong answers when asked if attorneys were required for writing ADs. A higher knowledge score was significantly associated with a higher attitude score (r=0.227, P<0.01). The women were more likely to be willing to write ADs in the future when they reported a middle income level rather than a lower income level (odds ratio [OR]=5.952, P<0.01), considered themselves unhealthy (OR=5.873, P<0.01), and graduated college or higher (OR=4.096, P<0.05). Furthermore, women who thought that ADs would have an impact on treatment (OR=1.869, P<0.05) and on their families (OR=1.447, P<0.05) were more likely to be willing to write an AD. Conclusion: This study shows that wrong information about ADs persists among middle-aged women, and significant factors associated with knowledge of and attitude toward ADs were identified. Targeted education programs about ADs need to be developed for middle-aged women.